Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study

Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has raised concerns in patients with inflammatory bowel disease (IBD), not only due to consequences of coronavirus disease 2019 itself but also as a possible cause of IBD relapse. The main objective of this study was to assess th...

Full description

Bibliographic Details
Main Authors: Alfredo Papa, Franco Scaldaferri, Marcello Covino, Antonio Tursi, Federica Furfaro, Giammarco Mocci, Loris Riccardo Lopetuso, Giovanni Maconi, Stefano Bibbò, Marcello Fiorani, Lucrezia Laterza, Irene Mignini, Daniele Napolitano, Laura Parisio, Marco Pizzoferrato, Giuseppe Privitera, Daniela Pugliese, Tommaso Schepis, Elisa Schiavoni, Carlo Romano Settanni, Lorenzo Maria Vetrone, Alessandro Armuzzi, Silvio Danese, Antonio Gasbarrini
Format: Article
Language:English
Published: MDPI AG 2022-04-01
Series:Biomedicines
Subjects:
SARS-CoV-2
inflammatory bowel disease
biological agents
Online Access:https://www.mdpi.com/2227-9059/10/4/843

Similar Items

Similar Items